Paradromics implants first brain-chip device in a human patient

Paradromics says it has implanted its Connexus brain-computer interface in a human patient for the first time, marking a major milestone for the Austin company as it pushes toward speech-restoration technology.

The procedure took place at University of Michigan Health in an FDA-approved clinical study. Paradromics described the patient as a Michigan woman with a motor neuron disease that impairs speech, and said her identity has not been disclosed.

Paradromics founder and CEO Matt Angle said the patient is recovering at home. He said the company expects to begin seeing the device "in action" within weeks, depending on how quickly she recovers.

A first long-term human implant

The company framed the surgery as its first human implant in an ongoing study, a different milestone from the temporary human test it reported in 2025. In that earlier procedure, Connexus was inserted during epilepsy surgery at the University of Michigan and later removed.

This new case is meant to test how the device performs over time rather than only in the operating room. Paradromics said the participant will be followed for six years as part of the study.

That long follow-up is intended to help the company evaluate both safety and communication performance before any broader clinical use.

What Connexus is designed to do

Connexus is designed to help people with severe motor impairments communicate by decoding speech-related brain signals and translating them into text or synthesized voice.

Paradromics has said the first clinical application for the system is assistive communication. The company has also described the device as roughly dime-sized and built with 421 microwires or electrodes that record neural activity.

The company has positioned Connexus as part of a competitive race among brain-computer interface developers trying to prove the technology can work reliably in patients.

What happens next

Paradromics said the next step is training and device-use testing once the patient has recovered enough to participate. The company expects to start seeing the implant used in practice within weeks, but that timeline depends on the patient’s condition.

During the six-year follow-up period, Paradromics said it will track safety, vocabulary size, words per minute and data throughput. Those measures will help determine whether the implant can support usable communication.

The company has not released full technical data from the case, and the patient’s privacy limits how much can be said publicly about the surgery itself.

For now, the case gives Paradromics its first long-term human implantation and a clearer path to testing whether Connexus can move from surgical milestone to real communication use.

Why it matters

The result matters because first-in-human milestones do not yet prove a brain-computer interface can deliver dependable performance outside the operating room. They do, however, show that a device has advanced far enough to begin longer-term human testing.

Paradromics is one of several companies racing to commercialize brain-computer interfaces, including Neuralink. The company’s success will now depend on whether this first implanted patient can safely use the system and whether the data support larger studies later on.